Clinical Outcomes in Cyclin-dependent Kinase 12 Mutant Advanced Prostate Cancer

Publication date: Available online 20 October 2019Source: European UrologyAuthor(s): Melissa A. Reimers, Steven M. Yip, Li Zhang, Marcin Cieslik, Mallika Dhawan, Bruce Montgomery, Alexander W. Wyatt, Kim N. Chi, Eric J. Small, Arul M. Chinnaiyan, Ajjai S. Alva, Felix Y. Feng, Jonathan ChouAbstractBackgroundCyclin-dependent kinase 12 (CDK12) loss occurs in 3–7% of metastatic prostate cancer patients and is characterized by a genomic instability signature, but the clinical implications of CDK12 loss are not well established.ObjectiveTo determine the clinical course of patients with CDK12 mutant advanced prostate cancer compared with other genomic subtypes.Design, setting, and participantsA retrospective analysis of data from three academic medical centers, including 317 patients with advanced prostate cancer and prior next-generation sequencing from tumor tissue (n = 172) or circulating tumor DNA (n = 145), was performed. Forty-six patients had CDK12 mutations; 34 had biallelic CDK12 loss (79%).Outcome measurements and statistical analysisPatients were stratified by mutation status (CDK12, homologous recombination deficiency [HRD; BRCA1/2 and ATM], TP53, and other cohort). The Kaplan-Meier method was used to evaluate time to event outcomes: time to development of metastatic disease, time to development of castration resistance, and time to prostate-specific antigen (PSA) progression after first-line androgen receptor pathway inhibitor (ARPI) therapy in a patient s...
Source: European Urology - Category: Urology & Nephrology Source Type: research

Related Links:

Authors: Montgomery B PMID: 31730580 [PubMed - in process]
Source: Clinical Advances in Hematology and Oncology - Category: Cancer & Oncology Tags: Clin Adv Hematol Oncol Source Type: research
Publication date: Available online 15 November 2019Source: Meta GeneAuthor(s): Berjas Abumsimir, Mohammed Mrabti, Abdelilah Laraqui, Ahmed Ameur, Saad Ibnsouda Koraishi, Mohammed Mzibrie, Mohammed Nabil Benchekroun, Hlima Bessi, Ikram Tiabi, Ihsan Almahasneh, Moulay Mustapha EnnajiAbstractThe home box transcription factor gene (HOXB13) plays a certain role in human development and prostate tumorgenesis. Genetic alterations of HOXB13 help to explore the suspected role in prostate cancer. To determine the prevalence and clinical correlates of high-frequent mutational events in home box transcription factor (HOXB13); DNA samp...
Source: Meta Gene - Category: Genetics & Stem Cells Source Type: research
Conclusion There is no research on the intraobserver agreement analysis of 68Ga–prostate-specific membrane antigen positron emission tomography/computed tomography in the literature. Our findings are the first ones. The intraobserver agreement was almost perfect. Moreover, although 68Ga–prostate-specific membrane antigen I&T positron emission tomography/computed tomography had moderate interobserver evaluation compliance of the primary tumour, it had excellent interobserver agreement levels in local lymph node metastasis and distant metastasis evaluation.4012501255
Source: Nuclear Medicine Communications - Category: Nuclear Medicine Tags: Original Articles Source Type: research
Objective Patients with prostate cancer are monitored by prostate-specific antigen (PSA) evaluation and PET [PET/computed tomography (CT)]. The aim of our study was to evaluate correlations between PSA levels and standardized uptake values (SUV) in patients with recurrent prostate cancer. Methods We analyzed 282 prostate cancer patients undergoing PET-CT due to suspicion of recurrence. Levels of PSA and PSA change per month were analyzed, together with maximum standardized uptake value (SUVmax). Results PET/CT results were positive in 175 patients (62.1%) and negative in 107 patients (37.9%). In the positive group,...
Source: Nuclear Medicine Communications - Category: Nuclear Medicine Tags: Original Articles Source Type: research
Conclusion Primary prostatic tumor seems less likely to respond to ADT than nodal or metastatic lesions. Residual primary uptake may guide patient selection for local therapy in (oligo) metastatic prostate cancer.
Source: Nuclear Medicine Communications - Category: Nuclear Medicine Tags: Original Articles Source Type: research
Publication date: November 2019Source: European Urology Supplements, Volume 18, Issue 11Author(s): L.H. Klotz, N. Axén, S. Grudén, C. Gauffin, J. Giddens, P. Incze, K. Jansz, M. Jievaltas, R. Rendon, A. Ulys, A. Bjartell, T. Tammela
Source: European Urology Supplements - Category: Urology & Nephrology Source Type: research
Publication date: November 2019Source: European Urology Supplements, Volume 18, Issue 11Author(s): L. Moris, T. Van Den Broeck, T. Gevaert, E. Smeets, C. Helsen, F. Handle, H. Van Poppel, W. Everaerts, D. Lambrechts, C. Buerki, E. Davicioni, D. Daelemans, S. Joniau, F. Claessens
Source: European Urology Supplements - Category: Urology & Nephrology Source Type: research
Publication date: November 2019Source: European Urology Supplements, Volume 18, Issue 11Author(s): G.S. Bora, V.K. Sharma, R.S. Mavuduru, S.K. Devana, N. Kakkar, A. Rastogi, A.P. Sharma
Source: European Urology Supplements - Category: Urology & Nephrology Source Type: research
Publication date: November 2019Source: European Urology Supplements, Volume 18, Issue 11Author(s): A. Sanchis-Bonet, C.A. Menor Galvan, E. Garcia Rico, D. Roman Curto, M. Sanchez Chapado, A. Bajo-Chueca
Source: European Urology Supplements - Category: Urology & Nephrology Source Type: research
Publication date: November 2019Source: European Urology Supplements, Volume 18, Issue 11Author(s): K.H. Shim, H.J Yoo, S.G Park, J.E Gwon, S.H Choo, J.B Choi, H.S Ahn, S.J Kim, S.I Kim
Source: European Urology Supplements - Category: Urology & Nephrology Source Type: research
More News: Academia | Cancer | Cancer & Oncology | Prostate Cancer | Statistics | Urology & Nephrology